HDAP/CHII      Contact Us      HIV Medication Chart      FAQs
PUBLICATIONS
Home › Publications › Journal Articles

Journal Articles

Mehta S, Cohen C, Taylor J. The fourteenth annual HIV drug guide. Positively Aware. March-April 2010.
Towner W, Lalezari J, Sension MG, Wohlfeiler M, Gathe J, Appelbaum J, et al. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. JAIDS: Journal of Acquired Immune Deficiency Syndromes. April 2010; 53(5): 614-618.
Cohen CJ. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clinical Trials. March-April 2009; 10(2): 116-124.
Boyle BA, Cohen CJ, DeJesus E, et al. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. The AIDS Reader. April 2009; 9(4): 158-160.
Cohen CJ. The ARTEMIS trial: Once-daily darunavir/ritonavir in the management of treatment-naïve, HIV-infected patients. HIV Therapy. March 2009; 3(2): 121-133.
Horne R, Kovacs C, Katlama C, Clotet B, Fumaz CR, Youle M, Kulasegaram R, Fisher M, Cohen C, Slim J, Shalit P, Cooper V, Tsoukas C. Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? AIDS Research and Therapy. February 2009; 6:2.
Arhad S, Rothberg M, Rastegar D, Spooner L, Skiest D. Survey of physican knowledge regarding antiretroviral medications in hospitalized HIV-infected patients. Journal of the International AIDS Society. February 2009; 12:1.
Boyle B, Cohen C, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Antiretroviral treatment update from the 48th ICAAC/46th IDSA Annual Meeting. The AIDS Reader. January 2009; 19(1): 22-31.
Simone M, Appelbaum J. HIV in older adults. Geriatrics: Better Medicine for Midlife and Beyond. December 2008; 63(12): 6-7.
Skiest DJ, Kambrink A, Su Z, Robertson KR, Margolis D. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. JAIDS: Journal of Acquired Immune Deficiency Syndromes. December 2008; 49(4): 377-383.
Boyle B, Cohen C, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Antiretroviral treatment update from the 17th International AIDS Conference. The AIDS Reader. November 2008; 18(11): 570-579.
Cohen C, Colson A, Pierone G, DeJesus E, Kinder F, Elion R, Skiest D, Habel A, Jensen J, Garb J, Schrager H. The FOTO study: 24-week results support the safety of a 2-day break on efavirenz-based antiretroviral therapy. Journal of the International AIDS Society 2008. November 10, 2008; 11(Suppl 1):019.
Iarikov D, Duke W, Skiest D. Extensive development of flat warts as a cutane manifestation of immune reconstitution syndrome. The AIDS Reader. October 2008; 18(10): 524-527.
Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, et al. Detection of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clinical Infectious Diseases. August 2008; 47(3): 421-4.
Vahey MT, Wang Z, Su Z, Nau ME, Rrambrink A, Skiest D, Margolis D. CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Research and Human Retroviruses. August 2008; 24(8): 1047-66.
Cenizal M, Hardy RD, Anderson M, Katz K, Skiest D. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes. August 2008; 48(5):567-571.
Elion R, Cohen CJ, Ward D, et al for the BATON Study Group. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabline given once daily. HIV Clinical Trials. July-August 2008; 9(4): 213-224.
Shah A, Tidswell M, Prefontaine M, Skiest DJ, Pantanowitz L. Choriocarcinoma in an AIds patient - relapsing but not fatal. International Journal of STD and AIDS. July 2008; 19(7): 496-98.
Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. Efficacy and tolerability of long term Efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS. January 2008; 22: 275-9.
Boyle B, Elion R, Cohen C, DeJesus E, Hawkins T, Moyle G. Advances in HIV theraputics: News from the 4th International AIDS Society Conference. The AIDS Reader. October 2007; 17(10):484-490.
Cohen C, Colson A. Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens. HIV Clinical Trials. 2007: 8(4):256.
Letter
(Registration Required)
Iarikov D, Roberts D, Granowitz E, Skiest D. Invasive aspergillosis presenting as a neck mass in a person with HIV/AIDS. The AIDS Reader. July 2007; 17(7): 343-344.
DeJesus E, Rodwick BM, Bowers D, Cohen CJ, & Pearce D. Use of dronabinol improves appetite and reverses weight loss in HIV/AIDS-infected patients. Journal of the International Association of Physicians in AIDS Care. June 2007; 6(2): 95-100.
Skiest D, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: A prospective study by AIDS Clinical Trials Group 5170. The Journal of Infectious Diseases. May 15, 2007; 195(10): 1426-1436.
Heelon M, Skiest D, Tereso G, Meade L, Weeks J, Pekow P, Rothberg M. Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients. American Journal of Health-System Pharmacy. May 2007; 64 (20): 2064-8.
Boyle BA, Elion R, Cohen CJ, et al. Advances in HIV therapeutics: The 14th CROI. The AIDS Reader. May 2007; 17(5): 268-286.
Not Available Online
Sharma A, Awasthi S, Harrod CK. Matlock EF, Khan S, Xu L, Chan S, Yang H, Thammavaram CK, Rasor RA, Burns DK, Skiest DJ, Van Lint C, Girard AM, McGee M, Monnat RJ Jr, Harrod R. The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication. Journal of Biological Chemistry. April 2007; 282(16): 12048-57.
Coskun ZU, Mathews D, Weatherall P, Skiest D, Oz OK. Cryptococcal lymphadenitis and massive splenomegaly in an immunocompromised patient. Clinical Nuclear Medicine. April 2007; 32(4): 314-6.
Vazquez JA, Skiest DJ, et al. Safety and efficacy of Posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clinical Trials. March-April, 2007; 8(2): 86-97.
Hill A, Grossman H, Cohen C, et al. Modeling-based prediction of clinical benefits from Etravirine in the TMC125-C223 trial. HIV Clinical Trials. March-April 2007; 8(2): 68-76.
Haubrich RA, Berger DB, Chiliade PC, Colson AD, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. March 30, 2007; 21(6): F11-F18.
Kessler HA, Boyle BA, Cohen CJ, et al. Assessing best practices in HIV/AIDS therapy. Changing Concepts in HIV Disease (CCHIV); March 2007.
Skiest DJ, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clinical Infectious Diseases. February 2007; 44(4): 607-614.
Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, & Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the Five-Days-On-Two-Days-Off (FOTO) study. HIV Clinical Trials. Jan/Feb 2007; 8(1): 19-23.
Boyle BA & Cohen CJ. NNRTIs: The next generation approaches. New York, NY: The Body Pro; 2007.
Sax PE, Cohen CJ, Kuritzkes DR, eds. HIV Essentials. Royal Oak, MI: Physicians' Press; 2007.
Cohen C. More hope coming with new HIV drugs, classes, and combos. Physician's Weekly. February 12, 2007; 24(7).
Cohen C. The next frontier in HIV: Battling drug resistance. Physician's Weekly. January 15, 2007; 24(3).
Elion R, Cohen C, DeJesus E, et al. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: A 48-week pilot study. HIV Clinical Trials. November/December 2006; 7(6): 324-333.
Article
(Registration Required)
El-Sadr WM, Lundgren, JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, et al. CD4+ count-guided interruption of antiretroviral treatment. The New England Journal of Medicine. 2006; 355(22):2283-96.
Skiest DJ, Brown K, Cooper TW, Hoffman-Roberts H, Mussa, HR, Elliott, AC. Prospective Comparison of Methicillin-susceptible and Methicillin-resistant Community Associated Staphylococcus aureus Infections in Hospitalized Patients. J. Infect. October 2006; 54: 427-434
Skiest DJ, Camelo-Piragua S, & Meade L. Painful oral ulcerations in patients with AIDS. The AIDS Reader. October 2006; 16(10): 531-532.
Not Available Online
Cohen C. Making progress in reducing the pill burden in HIV. Physician's Weekly. October 9, 2006; 13(38).
DeJesus E, Berger D, Markowitz M, Cohen C, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2006; 43(1):1-5.
Appelbaum JS, Elion R, Gallant JE, Henry K, Newman MD, Saag MS, Sax PE. Who should be providing HIV care? AIDS Clinical Care. 2006; 18(3): 21-24
Cohen CJ. Shoot for success. HIV Plus. April 2006:32-33.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy J, Stellbrink H, Lange J, Kuritzkes D, Eron J, Cohen C, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2005;40(4):413-421.
Cohen CJ. Ritonavir-boosted protease inhibitors, part 1: Strategies for balancing efficacy with effects on lipids. The AIDS Reader. 2005; 15 (9) 462-5, 470-1, 47, 477..
Swindells S, Cohen CJ, Berger DS, et al. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. BioMed Central Infectious Diseases. 2005;5(23).
Cohen CJ. EuroSIDA study confirms ability of most HAART regimens to decrease rates of illness and death. The Body. February 24, 2005.
Cohen CJ, Boyle BA. Antiretroviral therapy: The "when to start" debates. Clinical Infectious Disease. 2004;39:1705-1708.
Youle M, Cohen CJ, Katlama C, et al. Co-development of new antiretrovirals in very treatment-experienced HIV-infected individuals. The Lancet. 2004;364 (9439):1036-1037.
Letter
(Registration Required)
Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF;T-20) in combination with an optimized background regimen. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2004;37(1):1140-1146.
Cohen C. HIV and AIDS: A research and development update. Physician's Weekly. December 15, 2003; 20(47).
Cohen CJ, Hellinger JA, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clinical Trials. 2003;4(5):347-357.
Cohen C. First-line treatment in human immunodeficiency virus: Many paths to success. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2003; 33 (supplement 1): S29-S38.
Letter
(Registration Required)
Lalezari JP, Henry K, O'Hearn M, Montaner J, Piliero P, Trottier B, Walmsley S, Cohen C, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HI infection in North and South America. The New England Journal of Medicine. 2003;349(22):2175-2185.
The LD Study Group, et al. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. The Lancet. 2003;361:726-735.
Daar ED, Cohen C, Remien R., Sherer R, Smith K. Improving adherence to antiretroviral therapy. The AIDS Reader. 2003;13:81-90.
Lalezari JP, Eron JJ, Carlson M, Cohen C, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003;17(5):691-698.
Cohen CJ, Hunt S, Sension M, et al and the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16(4):579-588.
Colson AE, Sax PE, Keller MJ, Pettus PT, Platt R, Choo PW. Male sexual dysfunction associated with antiretroviral therapy. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2002;30(1):27-32.
Wheat LJ, Farthing C, Cohen CJ, et al., for the TIDBID (NR15520/M61018) study team. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection. Antiviral Therapy. 2002;7(3):199-209.
Tebas P, Henry K, Mondy K, Deeks S, Valdez H, Cohen C, Powderly W. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: Implications for intermittent therapeutic strategies. The Journal of Infectious Diseases. 2002; 186: 851-4.
Cohen CJ, Dusek A, Green J, Johns EL, Nelson E, Recny MA. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care and STDs. 2002;16(7):327-335.
Colson AE, Sax PE, Keller MJ, et al. Paronychia in association with indinavir treatment. Clinical Infectious Diseases. 2001;32(January 1):140-143.
Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. The cost-effectiveness of combination antiretroviral therapy in HIV. New England Journal of Medicine. 2001;344(11):824-831.
Weinstein MC, Goldie SJ, Losina E, Cohen CJ et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Annals of Internal Medicine. 2001;134(6):440-450.
Verbiest W, Brown S, Cohen CJ, et al. Prevalence of HIV-1 drug resistance in antiretroviral-naïve patients: a prospective study. AIDS. 2001;15(5):647-650.
Lalezari JP, Beal JA, Ruane PJ, Cohen CJ et al. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial. HIV Clinical Trials. 2000;1(3):1-15.
Hellinger JA, Cohen CJ, Stein A, Gallant J, Gathe J, Keiser, P. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy. HIV Clinical Trials. 2000;1(2):25-28.
Beatty MA, Cohen CJ, Coady W, et al. Expanded access: the experiences of one research site. Research Practitioner. 2000;1(5).
Colven R, Harrington RD, Spach DH, Calvin CJ, et al. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Annals of Internal Medicine. 2000;133(6):430-434
Colson AE, Sax PE. Sexual dysfunction and HIV infection. Aids Clinical Care. 2000;12(3).
Not Available Online
DeMaria, Jr. A, Kunches L, Mayer K, Cohen C et al. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gpl160 working group. Journal of Human Virology. 2000;3(4):182-92.
Cohen CJ, Piliero PJ, Pile OH, et al. Increasing treatment adherence in the correctional setting: Current efforts to simplify protease inhibitor dosing regimens. Journal of Correctional Health Care. 2000;7(1).
Not Available Online
Cohen CJ, Hellinger JA, Norris D, et al. Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection. The AIDS Reader. 2000;10(5):296-313.
Hellinger JA, Iwane MK, Smith JJ, Fleishman AN, Torres RA, Schrader S, Perez G, Cohen CJ et al. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. The Journal of Infectious Diseases. 2000;181(2):540-547.